Virginia Drug Discovery Consortium
The Virginia Drug Discovery Consortium (VaDDC) has a threefold mission:
To promote the growth and advancement of drug discovery and development programs at universities and research institutes within Virginia, particularly through inter-institutional collaboration.
To help the pharmaceutical industry bring life-saving and quality of life solutions to patients through innovative collaborations with Virginia’s best and brightest researchers.
To promote and enhance the attractiveness of Virginia as an environment for pharmaceutical and biotech companies.
EVENTS
The VaDDC Executive Committee is pleased to announce the VirginiaDrugDiscoveryRx: Emerging Targets, Technologies, and Therapeutics for Cancer and Neuroscience meeting was held at the
Hotel Roanoke – May 21, 22, 2019
See Details for the Meeting on our Events Page.
Thank you to our sponsors whose participation in the
VirginiaDrugDiscoveryRx: Emerging Targets,Technologies, and Therapeutics Symposium
held at the
Hotel Roanoke, May 21-22, 2019
was key to the meeting’s success.
- Medicines for All Institute – VCU
- Advion
- Carilion Clinic
- City of Roanoke Department of Economic Development
- Fralin Biomedical Research Institute
- University of Virginia – Licensing & Ventures Group
- University of Virginia – Brain Institute
- University of Virginia – Cancer Center
- Virginia Biosciences Health Research Corporation
- Virginia Commonwealth University – Innovation Gateway
- Virginia Commonwealth University – Massey Cancer Center
- Virginia Tech – LINK
- BrightSpec
- Buchi
- Virginia Tech – Outreach & International Affairs
- Sciex
- Woods Rogers PLC
- KeViRx
- New River Valley IP Law
- Schrodinger
NEWS
Virginia Bio Names John Newby CEO
Virginia Bio announces John Newby will become CEO of Virginia Bio starting August 5, 2019. John will be stepping down as Commissioner of the Virginia Department of Veterans Services, where for the last 7 years he led this 800-member Agency located across more than 40...
Webster Santos – VT and Kevin Lynch-UVA received a $2.8 NIAID grant to Develop a Drug to Treat Multiple Sclerosis
Santos received this research grant in collaboration with Kevin Lynch, a professor of pharmacology at the University of Virginia. Lynch will oversee the biological testing of the drug. The NIAID award builds on an existing research grant from the National Institute of...
NIH Provides $23 million for Statewide Translational Research Institute
The integrated Translational Health Research Institute of Virginia (iTHRIV) has been awarded a five-year grant of nearly $23 million from the National Institutes of Health (NIH) to advance innovative ideas from the point of discovery to implementation in clinical...
AFFILIATES
Want to work with us?
If you are interested in supporting this initiative, please contact us.